Zydus Lifesciences gets USFDA EIR for formulation manufacturing facility at SEZ 2, Ahmedabad
Ahmedabad: Zydus Lifesciences has announced that the company has received the Establishment Investigation Report (EIR) report from the United States Food and Drug Administration (USFDA) for the inspection conducted at the formulation manufacturing facility named ‘SEZ 2’ located at Pharmez, Ahmedabad from 3rd to 7th July, 2023.
This was a Pre-Approval Inspection (PAI) and had concluded with NIL observations.
Read also: Zydus Lifesciences concludes USFDA inspection at Ahmedabad facility with nil observations
Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an Indian Pharmaceutical company headquartered in Ahmedabad. The Company was founded in the year 1952 by Mr. Ramanbhai B. Patel (late), a first-generation entrepreneur and a doyen in the field of Indian Pharmaceuticals. It is primarily engaged in the manufacture of generic drugs.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.